POWERWAVE TECHNOLOGIES INCORPORATED (NASDAQ: PWAV) "Up 41.55% on Monday"
Powerwave Technologies, Inc. engages in the design, manufacture, marketing, and sale of wireless solutions for wireless communications networks worldwide. The company offers antennas, boosters, combiners, cabinets, shelters, filters, radio frequency power amplifiers, remote radio head transceivers, repeaters, tower-mounted amplifiers, and advanced coverage solutions for use in frequency bands, including cellular, PCS, 3G, and 4G wireless communications networks. It sells its products through its direct sales force, independent sales representatives, and resellers to wireless original equipment manufacturers and individual wireless network operators. The company was formerly known as Milcom International, Inc. and changed its name to Powerwave Technologies, Inc. in June 1996. Powerwave Technologies, Inc. was founded in 1985 and is based in Santa Ana, California.
CLEAN DIESEL TECHNOLOGIES INCORPORATED (NASDAQ: CDTI) "Up 55.95% on Monday"
Clean Diesel is a vertically integrated global manufacturer and distributor of emissions control systems and products, focused on the heavy duty diesel and light duty vehicle markets. Clean Diesel utilizes its proprietary patented Mixed Phase Catalyst (MPC®) technology, as well as its ARIS® selective catalytic reduction, Platinum Plus® fuel-borne catalyst, and other technologies to provide high-value sustainable solutions to reduce emissions, increase energy efficiency and lower the carbon intensity of on- and off-road engine applications. Clean Diesel is headquartered in Ventura, California and currently has operations in the U.S., Canada, U.K., France, Japan and Sweden.
OREXIGEN THERAPEUTICS INCORPORATED (NASDAQ: OREX) "Up 18.65% on Monday"
Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its lead combination product candidates include Contrave, which has completed Phase III clinical trials; and Empatic that has completed Phase II clinical trials. Contrave is a combination of two drugs, bupropion and naltrexone, in a sustained release formulation (SR). Bupropion is an antidepressant and smoking cessation medication; naltrexone is a treatment for alcohol and opioid addiction. The company’s Empatic product candidate is a combination of bupropion SR and zonisamide SR. Zonisamide, in an immediate release formulation for the adjunctive treatment of partial seizures, a form of epilepsy. The company was founded in 2002 and is based in La Jolla, California.
About OTCPicks.com
OTCPicks.com, one of the leading penny stock Web sites, presents its daily Stocks to Watch and Midday Market Movers every weekday. In addition to all the latest penny stock news, OTCPicks also offers daily newsletters, unique commentaries and free profiles, alerts and investing tips.
The stocks presented above are available in OTCPicks.com's Free Daily Email Newsletter. For daily stock alerts go to www.otcpicks.com to sign up.
Disclosure: OTCPicks.com and affiliates have been not been compensated by any of the companies covered in this release.
